Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Colonization factor surface antigen 2 (CS2) is a critical fimbrial adhesin expressed by Enterotoxigenic Escherichia coli (ETEC), a leading cause of bacterial diarrhea worldwide [1]. It belongs to the Colonization Factor Antigen II (CFA/II) group, which also includes CS1 and CS3, and is responsible for the initial attachment of the pathogen to the human small intestinal epithelium [2]. This adherence is a prerequisite for the delivery of heat-labile (LT) and heat-stable (ST) enterotoxins that trigger fluid secretion and secretory diarrhea [3]. Because of its essential role in pathogenesis and its high prevalence in clinical isolates, CS2 is a major component in several candidate ETEC vaccines, such as the oral inactivated whole-cell vaccine ETVAX [4]. Therapeutic strategies focus on eliciting a robust mucosal immune response, specifically secretory IgA, to neutralize the adhesin and prevent bacterial colonization [5].
Induction of mucosal IgA antibodies that block bacterial adhesion to intestinal epithelial cells, preventing colonization and subsequent toxin delivery.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Colonization factor surface antigen 2 (CS2) (CS2).